Novavax, Inc. (NVAX)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
As of 12:05PM EDT. Market open.
| Previous Close | 12.70 |
| Open | 12.75 |
| Bid | 12.31 x 100 |
| Ask | 12.48 x 100 |
| Day's Range | 12.34 - 12.91 |
| 52 Week Range | 3.53 - 23.86 |
| Volume | |
| Avg. Volume | 7,476,422 |
| Market Cap | 1.985B |
| Beta (5Y Monthly) | 2.04 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.62 |
| Earnings Date | Nov 07, 2024 - Nov 11, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 20.00 |
ZacksNovavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It
Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Investor's Business DailyNovavax Stock Rocketed This Year, But Challenges Persist. Is It A Buy Or A Sell?
Novavax stock remains volatile. After hitting a two-year high in June on enthusiasm for its updated Covid vaccine, shares have pulled back.
ZacksBiotech Stock Roundup: NVAX Vaccine Approval, ALNY, ATHA Stock Dive on Updates & More
Novavax and Alnylam are in the spotlight following drug approval and regulatory updates, respectively.
© 2024 Yahoo. All rights reserved.